Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?
Executive Summary
Excitement to get a 10-month ANDA review may have waned in January as submissions plummet, but can approvals keep up?
You may also be interested in...
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.